Celularity Secures $12.2M from New Jersey Tax Credit Sale
Event summary
- Celularity received $12.2M from the sale of $126.3M in New Jersey net operating losses (NOLs) and $1.9M in R&D tax credits.
- The sale was conducted through New Jersey’s Technology Business Tax Certificate Transfer Program.
- Funds will strengthen Celularity’s balance sheet and support commercial opportunities in stem cell and regenerative medicine.
- Robert J. Hariri, M.D., Ph.D., Chairman and CEO, highlighted the non-dilutive nature of the capital.
The big picture
Celularity’s $12.2M tax credit sale underscores the strategic importance of state-level incentives for biotech firms, particularly those focused on regenerative medicine. The non-dilutive capital injection aligns with broader industry trends where companies leverage tax programs to bolster balance sheets and fund innovation without diluting equity. This move positions Celularity to accelerate its commercialization efforts in a competitive market driven by advancements in cellular therapies and longevity solutions.
What we're watching
- Capital Allocation
- How Celularity will deploy the $12.2M to advance its commercial opportunities in stem cell and regenerative medicine.
- Program Efficacy
- The pace at which New Jersey’s Technology Business Tax Certificate Transfer Program can provide similar non-dilutive funding to other biotech firms.
- Market Positioning
- Whether the infusion of capital will enhance Celularity’s competitive edge in the longevity-focused regenerative medicine space.
Related topics